Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
NCT05447494
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Gaucher Disease, Type 1
Gaucher Disease, Type 3
Interventions
DRUG:
Low-dose CAN103
DRUG:
High-dose CAN103
Sponsor
CANbridge (Suzhou) Bio-pharma Co., Ltd.